Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).
DR Camidge, SHI Ou, G Shapiro, GA Otterson… - 2014 - ascopubs.org
8001 Background: c-Met-amplified NSCLC defines a subset of NSCLC that may be sensitive
to the small-molecule tyrosine kinase inhibitor crizotinib, approved multinationally for the …
to the small-molecule tyrosine kinase inhibitor crizotinib, approved multinationally for the …
Efficacy and safety of axitinib in patients with advanced non–small-cell lung cancer: results from a phase II study
JH Schiller, T Larson, SHI Ou, S Limentani… - Journal of clinical …, 2009 - ascopubs.org
… Lung cancer is a major cause of morbidity and mortality. In the United States, it is the leading
cause of cancer … survival rate for lung cancer is only 15%, among the lowest relative to other …
cause of cancer … survival rate for lung cancer is only 15%, among the lowest relative to other …
Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis
X Jia, L Geng, M Jiao, W Wang, L Jiang, H Guo - Lung Cancer, 2020 - Elsevier
… Lung cancer is a major threat to human health. The 2018 global cancer statistics reported that
lung cancer … cell lung cancer (including squamous cell lung cancer, lung adenocarcinoma, …
lung cancer … cell lung cancer (including squamous cell lung cancer, lung adenocarcinoma, …
Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
S Wang, J Hao, H Wang, Y Fang, L Tan - Oncoimmunology, 2018 - Taylor & Francis
… Immune checkpoint inhibitors (ICIs) are new therapeutic strategies for non-small cell lung
cancer (NSCLC). We aimed to quantitatively evaluate the efficacy and safety of ICIs in NSCLC. …
cancer (NSCLC). We aimed to quantitatively evaluate the efficacy and safety of ICIs in NSCLC. …
[HTML][HTML] … efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non–small cell lung cancer …
DR Camidge, R Dziadziuszko, S Peters, T Mok… - Journal of Thoracic …, 2019 - Elsevier
… efficacy with ALK inhibitors, including alectinib.3, 8 Here we report updated efficacy and safety
… 1, 2017) and an exploratory analysis of efficacy by EML4-ALK fusion variant. We discuss …
… 1, 2017) and an exploratory analysis of efficacy by EML4-ALK fusion variant. We discuss …
Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer
G Luporini, S Barni, E Marchi… - European Respiratory …, 1998 - Eur Respiratory Soc
… In this study, we examined the efficacy and safety of a short-term treatment with … due to
primary lung cancer or metastatic cancer to the lungs. Efficacy and safety of levodropropizine and …
primary lung cancer or metastatic cancer to the lungs. Efficacy and safety of levodropropizine and …
[HTML][HTML] Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III …
NB Leighl, P Zatloukal, J Mezger, R Ramlau… - Journal of Thoracic …, 2010 - Elsevier
… In conclusion, these results support the efficacy and safety profile of bevacizumab-… lung
cancer therapies in this patient group. With greater inclusion of older patients in lung cancer trials…
cancer therapies in this patient group. With greater inclusion of older patients in lung cancer trials…
Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors
A Patnaik, LS Rosen, SM Tolaney, AW Tolcher… - Cancer discovery, 2016 - AACR
We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor
activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 …
activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 …
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
S Ricciardi, S Tomao, F de Marinis - Lung Cancer: Targets and …, 2010 - Taylor & Francis
… Lung cancer is the leading cause of cancer deaths worldwide. Approximately 400,000 new
cases of lung cancer are diagnosed every year in Europe; lung … cancers in men. Citation1 …
cases of lung cancer are diagnosed every year in Europe; lung … cancers in men. Citation1 …
[HTML][HTML] Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis
F Griesinger, EE Korol, S Kayaniyil, N Varol, T Ebner… - Lung Cancer, 2019 - Elsevier
… of first-line (1L) therapy for advanced non-small cell cancer (NSCLC). The objective of this
study was to evaluate the relative efficacy, safety, and health-related quality of life (HRQoL) of …
study was to evaluate the relative efficacy, safety, and health-related quality of life (HRQoL) of …